The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Parkinson's disease (PD) affects the nerves of the entire gastrointestinal (GI) tract and may result in profound gastrointestinal (GI) dysfunction leading to poor patient outcomes. Common GI disturbances in patients with PD include gastroparesis (GP), constipation and small intestinal bacterial overgrowth syndrome (SIBO). In particular, GP is difficult to treat due to the limited options available and precautions, contraindications and adverse effects associated with the approved treatments. Moreover, some commonly used medications can worsen pre-existing PD. AREAS COVERED: Our review will focus on treatment options for GP and SIBO with motilin agonists, dopamine receptor antagonists, Ghrelin agonists muscarinic agonists, 5-HT4 receptor agonists, antibiotics, probiotics and herbal formulation such as iberogast. Constipation occurs in the majority of patients with PD and fortunately many treatments are now available. Our review is based on original papers or reviews selected from PUBMED search and Cochrane reviews. EXPERT OPINION: Motility disorders of the GI tract are found frequently in patients with PD and treating the underlying GI disorders caused by PD with various prokinetics and laxatives is paramount in achieving improvements in patient's motor function. Various prokinetics and laxatives are now available to provide some relief of the GI morbidity caused by PD leading even to better absorption of even the PD treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354 · cited 1×
“PD likely damages the nerves of the entire GI tract, including the esophagus, stomach, small bowel, colon and rectum [10,11].”
BackgroundSeppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141 · cited 3×
“Based on this pivotal trial, the Movement Disorder Society Evidence Based Review Update on the Treatments for the non-motor symptoms of PD rated PEG as likely efficacious for the treatment of constipation in PD without a requirement for any specialized monitoring [12].”
BackgroundMethodInfluentialRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 2×
“The Phase III, placebo-controlled RCTs, TARGET 1 and 2 trials, showed that a 2-week treatment of rifaximin has shown relief of IBS symptoms, bloating, abdominal pain and loose/watery stools in patients with IBS without constipation [86].”
BackgroundMethodParkman, H. P., Hasler, W. L., & Fisher, R. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.055 · Cited by 738 · cited 2×
“2 Gastroparesis GP is a chronic GI condition involving the stomach and is defined as a delayed gastric emptying in the absence of mechanical obstruction [18].”
BackgroundLembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
A placebo-controlled trial of prucalopride for severe chronic constipation
Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800670 · Cited by 576 · cited 1×
“Although prucalopride improves constipation in the general population [42], it may not be an effective option in patients with PD.”
BackgroundSoykan, I., Sivri, B., Sarosiek, I., Kiernan, B., & Mccallum, R. W. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1026665728213 · Cited by 575 · cited 1×
“5% of cases of GP and is a common cause of this dysfunction across all neurologic diseases [20].”
BackgroundTwo randomized trials of linaclotide for chronic constipation
Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010863 · Cited by 373 · cited 2×
“Guanylate Cyclase C Receptor Peptide: Promotes the generation of cyclic guanosine monophosphate that secretes chloride and bicarbonate into the intestinal lumen, increasing luminal fluid secretion and accelerating intestinal transit [38] Linaclotide: 145 -- 290 mcg QD Not evaluated in PD.”
BackgroundThe role of small intestinal bacterial overgrowth in Parkinson's disease
Fasano, A., Bove, F., Gabrielli, M., Petracca, M., Zocco, M. A., Ragazzoni, E., Barbaro, F., Piano, C., Fortuna, S., Tortora, A., et al. (2013) · Movement Disorders · doi:10.1002/mds.25522 · Cited by 344 · cited 3×
“Collectively, this can lead to an overall worsened motor function compared to patients without SIBO [8,9,27].”
Background
Cited by
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Self-citationACG Clinical Guideline: Small Intestinal Bacterial Overgrowth
Pimentel, M., Saad, R. J., Long, M. D., & Rao, S. S. C. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000501 · Cited by 502
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392
Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease
Caputi, V., & Giron, M. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061689 · Cited by 338
The gut-brain axis and Parkinson disease: Clinical and pathogenetic relevance
Menozzi, E., Macnaughtan, J., & Schapira, A. H. V. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1890330 · Cited by 81
Metadata
- Authors
- Barboza, J. L., Okun, M. S., & Moshiree, B.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2015-09-16
- Volume
- 16
- Issue
- 16
- Pages
- 2449-2464
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1667748414
- Cited by
- 77
- References
- 24
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease. https://app.cochat.ai/papers/10.1517/14656566.2015.1086747
- The paper
- Barboza, J. L., Okun, M. S., & Moshiree, B. (2015). The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.2015.1086747
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.